Pridopidine

Pridopidine is a drug that is currently under investigation for its potential use in the treatment of Huntington's disease. It is a dopamine stabilizer that was originally developed by NeuroSearch, and is now being developed by Prilenia Therapeutics.

Mechanism of action

Pridopidine acts as a dopamine D2 receptor antagonist, and has a high affinity for sigma-1 receptors. The drug's mechanism of action is not fully understood, but it is believed to improve motor function and reduce motor symptoms in patients with Huntington's disease.

Clinical trials

Several clinical trials have been conducted to evaluate the safety and efficacy of pridopidine in patients with Huntington's disease. The results of these trials have been mixed, with some showing a significant improvement in motor function, while others have shown no significant difference between pridopidine and a placebo.

Side effects

The most common side effects of pridopidine include nausea, fatigue, and insomnia. In rare cases, pridopidine can cause serious side effects such as akathisia and dyskinesia.

Future developments

Research is ongoing to determine the long-term effects of pridopidine and its potential use in other neurodegenerative diseases. Prilenia Therapeutics is currently conducting a Phase III clinical trial to further evaluate the drug's efficacy and safety.

See also

• Huntington's disease
• Dopamine D2 receptor
• Sigma-1 receptor

File:WHO Rod.svg This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia